drugset / Trial / NCT00551473

Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.

NCT00551473

Phase 1 Completed 18 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Current treatment for gastroesophageal reflux disease(GERD)confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric acid suppression. Clinical data on lavoltidine demonstrates a rapid onset of action, high potency, and prolonged duration of effect after single dose. Since tolerance to the class of compounds to which lavoltidine belongs may be dose dependent, the current study is designed to determine if 40mg lavoltdine given for 7days develops tolerance.

Timeline

Start
2007-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lavoltidine Small molecule 40 mg